StockData
KURANasdaqPharmaceutical PreparationsFiscal year ends December 31

Kura Oncology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$9.36+0.28 (+3.08%)

Close on Oct 19, 2026

Market cap
$831.68M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 3, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 12, 2026During market hours$20.87M$-0.77–
Q1 FY2026
Ended Mar 31, 2026
May 12, 2026During market hours$18.27M$-0.83–
Q4 FY2025
Ended Dec 31, 2025
Mar 5, 2026Before market open$17.34M$-0.92–
Q3 FY2025
Ended Sep 30, 2025
Nov 4, 2025Before market open$20.80M$-0.85–
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025During market hours$15.30M––
Q1 FY2025
Ended Mar 31, 2025
May 1, 2025During market hours$14.10M$-0.66–
Q4 FY2024
Ended Dec 31, 2024
Feb 26, 2025During market hours$53.90M––
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024During market hours–––
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024During market hours–$-0.59–
Q1 FY2024
Ended Mar 31, 2024
May 2, 2024During market hours–––
Q4 FY2023
Ended Dec 31, 2023
Feb 27, 2024During market hours–––

Company guidance

Outlook given with results on Jan 12, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
non-cash collaboration revenue recognition2026$45.00M to $55.00MNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Kura Oncology filed with the SEC